Skip to main content
Premium Trial:

Request an Annual Quote

Silence Reports Higher 1H Loss on Special Charge


Silence Therapeutics last month released its financial results for the first six months of 2012, reporting a sharply increased net loss on charges related to its decision to drop its license to certain RNAi intellectual property.

For the six-month period ended June 30, Silence's net loss jumped to £25.5 million ($40.8 million), compared with £3.4 million in the same period a year earlier. Driving the loss up was a £20.4 million write-off of goodwill related to Intradigm, a California-based RNAi drug developer acquired by Silence in 2010.

One of Intradigm's key assets was a license from the University of Massachusetts to the so-called Zamore Design Rules IP, which relate to methods of producing modified double-stranded agents with decreased off-target silencing activity. Earlier this year, Silence opted to end its license to the IP, citing cost constraints (GSN 7/12/2012). Doing so prompted the goodwill write-off, Silence said.

Excluding the extraordinary charge, Silence's net loss for the first half of this year was £2.9 million.

Revenues in the six-month period were £40,000, compared with £350,000 last year, reflecting lower income from license partners, while research and development spending remained essentially flat at £1.9 million.

Silence had £950,000 in cash on hand at the end of the half-year period, but recently raised £6.45 million, which is expected to fund its operations into the second half of 2014.

The company reiterated its expectation that it will begin a phase Ib study of its sole clinical candidate, the cancer treatment Atu027, by late 2012 or early 2013.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.